Genmab A/S ADS (GMAB)
GMAB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1434265/000143426526000014/0001434265-26-000014-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | GMAB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Denmark |
| IPO year | 2019 |
| SEC CIK | 0001434265 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.7B |
| Net income | $963.0M |
| Operating income | Not in SEC XBRL data |
| Net margin | 25.9% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | 23.7× |
| P/S (computed) | 6.1× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2019-07-19 |
| Latest annual report | 20-F | 2026-02-17 |
| Latest quarterly / interim | 6-K | 2026-10-13 |
Source: SEC EDGAR submissions feed, 563 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.1% |
| 1 month | +8.5% |
| 3 months | +27.8% |
| Year to date | +20.3% |
| 1 year | +13.4% |
| From 52-week high | -3.7% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| UTHR | United Therapeutics Corporation | $543.40 | -1.22% | $23.3B |
| ROIV | Roivant Sciences Ltd. Common Shares | $33.35 | -3.58% | $24.1B |
| INSM | Insmed Incorporated | $96.79 | -1.80% | $21.1B |
| VTRS | Viatris Inc. | $17.25 | -1.65% | $19.8B |
| ALNY | Alnylam Pharmaceuticals Inc. | $223.82 | -1.41% | $29.9B |
| ZTS | Zoetis Inc. | $74.30 | -1.78% | $30.7B |
| RPRX | Royalty Pharma plc Class A Ordinary Shares | $56.57 | -2.09% | $32.5B |
| ASND | Ascendis Pharma A/S Ordinary Share | $223.21 | -1.67% | $14.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier